LKB1-AMPK axis negatively regulates ferroptosis by inhibiting fatty acid synthesis

Changzhi Li, Xuan Dong, Wenjing Du, Xin Shi, Kangjie Chen, Wei Zhang, Minghui GaoSignal 2020 · DOI · OpenAlex

Abstract

Ferroptosis is a form of regulated necrotic cell death characterized by an iron-dependent lipid peroxidation. Although mounting evidence has demonstrated that diverse cellular metabolic processes contribute to ferroptosis, the detail mechanism by which cellular metabolism regulates ferroptosis is largely unknown. Here, we demonstrated that AMP-activated protein kinase (AMPK), a highly conversed master regulator of cellular energy homostasis is a crucial negative regulator of ferroptosis. Activation of AMPK by glucose starvation or a pharmaceutical activator suppresses ferroptotic cell death, and genetic knocking out of AMPK sensitizes cells to ferroptosis. Mechanistically, ferroptosis inducers activate AMPK which in turn phosphorylates acetyl-CoA carboxylase 1 (ACC1), leading to inhibition of fatty acid synthesis, lipid peroxide accumulation and ferroptosis. Importantly, loss of function of tumor suppressor liver kinase B1 (LKB1) sensitizes mouse embryonic fibroblasts (MEFs) and human non-small cell lung carcinoma cell lines to ferroptosis. Collectively, our results demonstrate the vital role of LKB1-AMPK-ACC1-FAS axis in dictating ferroptotic cell death, and suggest that malignant mutations in LKB1-AMPK signalling could predict the responsiveness of cancer cells to future ferroptosis-inducing therapies.

Introduction

Ferroptosis is a distinct form of regulated cell death driven by the accumulation of iron-dependent lipid peroxides (essentially, "rusted" fats in the cell membrane). While previous research has linked metabolic states—particularly glucose and glutamine metabolism—to ferroptosis sensitivity, the specific molecular pathways connecting energy sensing to cell survival remain poorly understood. This study investigates the role of AMP-activated protein kinase (AMPK), the cell's primary energy sensor, in modulating ferroptosis when antioxidant defenses, such as the GPX4 enzyme, are compromised.

Methods

The researchers employed a multi-faceted approach using Mouse Embryonic Fibroblasts (MEFs) and human Non-Small Cell Lung Cancer (NSCLC) cell lines (H1299, H838, H1975, H358). Genetic manipulation was achieved via CRISPR/Cas9 to generate AMPK double-knockout (DKO) and LKB1-deficient lines. Pharmacological tools included AMPK activators (AICAR), inhibitors (Compound C), and downstream pathway inhibitors targeting ACC1 (ND-630) and FAS (Orlistat). Cell death was quantified using propidium iodide staining and flow cytometry, while lipid peroxidation was measured via the fluorescent probe BODIPY C11.

Results

AMPK as a Protective Metabolic Brake

Experimental results demonstrated that AMPK acts as a critical negative regulator of ferroptosis. Activation of AMPK, whether through glucose starvation or pharmacological agents, significantly suppressed ferroptotic cell death induced by the ferroptosis-inducing agents (FINs) erastin or RSL3. Conversely, AMPK DKO cells exhibited heightened sensitivity, characterized by accelerated death and increased lipid hydroperoxide accumulation compared to wild-type cells.

Experimental validation of the LKB1-AMPK axis in regulating ferroptosis across various cell models and treatments.

The LKB1-ACC1-FAS Signaling Cascade

The study identified LKB1 as the essential upstream kinase for AMPK activation in this context. Reconstitution of wild-type LKB1 in naturally null lung cancer cells (H838) restored resistance to ferroptosis, whereas a kinase-dead mutant failed to do so. Mechanistically, activated AMPK phosphorylates and inhibits Acetyl-CoA Carboxylase 1 (ACC1), which in turn limits the activity of Fatty Acid Synthase (FAS). This inhibition reduces the synthesis of fatty acids required for the formation of lethal lipid peroxides. Pharmacological inhibition of ACC1 (with ND-630) or FAS (with Orlistat) was sufficient to rescue AMPK-deficient or LKB1-deficient cells from ferroptosis, confirming that the protective effect of AMPK is mediated through the suppression of fatty acid synthesis.

Discussion and Conclusion

This research establishes the LKB1-AMPK-ACC1-FAS axis as a major metabolic pathway governing ferroptosis sensitivity. The findings suggest that cancers harboring LKB1 mutations—common in lung and cervical malignancies—may be uniquely vulnerable to ferroptosis-inducing therapies due to the loss of this protective metabolic brake.

Schematic model illustrating how the LKB1-AMPK axis inhibits fatty acid synthesis to prevent lipid ROS accumulation and ferroptosis.

While this study provides a clear mechanistic link in vitro, future work must focus on in vivo validation of these mechanisms in animal models. Additionally, the potential for LKB1 status to serve as a clinical biomarker to guide the use of ferroptosis-inducing drugs in oncology warrants further investigation.

Summary updated

Abstract

Ferroptosis is a form of regulated necrotic cell death characterized by an iron-dependent lipid peroxidation. Although mounting evidence has demonstrated that diverse cellular metabolic processes contribute to ferroptosis, the detail mechanism by which cellular metabolism regulates ferroptosis is largely unknown. Here, we demonstrated that AMP-activated protein kinase (AMPK), a highly conversed master regulator of cellular energy homostasis is a crucial negative regulator of ferroptosis. Activation of AMPK by glucose starvation or a pharmaceutical activator suppresses ferroptotic cell death, and genetic knocking out of AMPK sensitizes cells to ferroptosis. Mechanistically, ferroptosis inducers activate AMPK which in turn phosphorylates acetyl-CoA carboxylase 1 (ACC1), leading to inhibition of fatty acid synthesis, lipid peroxide accumulation and ferroptosis. Importantly, loss of function of tumor suppressor liver kinase B1 (LKB1) sensitizes mouse embryonic fibroblasts (MEFs) and human non-small cell lung carcinoma cell lines to ferroptosis. Collectively, our results demonstrate the vital role of LKB1-AMPK-ACC1-FAS axis in dictating ferroptotic cell death, and suggest that malignant mutations in LKB1-AMPK signalling could predict the responsiveness of cancer cells to future ferroptosis-inducing therapies.
BibTeX
@inproceedings{li2020lkb,
  author = {Changzhi Li and Xuan Dong and Wenjing Du and Xin Shi and Kangjie Chen and Wei Zhang and Minghui Gao},
  title = {{LKB1-AMPK axis negatively regulates ferroptosis by inhibiting fatty acid synthesis}},
  booktitle = {Signal},
  year = {2020},
  doi = {10.1038/s41392-020-00297-2},
}
Figure